1. Chen KY, Lu CS, Pang CY, Ho CJ, Wu KC, Yang HW, Lai HL, Chern Y, Lin CJ*. Equilibrative nucleoside transporter 1 is a target to modulate neuroinflammation and improve functional recovery in mice with spinal cord injury. Molecular Neurobiology 2023; 60:369-381.(*The corresponding author) (SCI)

2. Chen CY, Chou FY, Chang YG, Ho CJ, Hsu CL, Chern Y, Lin CJ*. Deletion of equilibrative nucleoside transporter 2 disturbs energy metabolism and exacerbates disease progression in an experimental model of Huntington’s disease. Neurobiology of Disease 2023; 177:106004. (*The corresponding author) (SCI)

3. Zhang NY, Wang TH, Chou CH, Wu KC, Yang CR, Kung FL, Lin CJ*. Ibuprofen treatment ameliorates memory deficits in rats with collagen-induced arthritis by normalizing aberrant MAPK/NF-κB and glutamatergic pathways. European Journal of Pharmacology 2022; 933:175256. (*The corresponding author) (SCI)

4. Kaibara A, Peng A, Xie R, Ho YF, Lin CJ, Tham LS, Mallayasamy S, Sathirakul K, Lo YL, Tran MH, Pham VT, Kharis Nugroho A, Myo Oo K, Kunwar B, Mannapperuma U, Ya K, Usman M, Ming LC, Park K. The Asian Pharmacometrics Network: The historical background, establishment, objectives and roles, and recent activities. CPT Pharmacometrics Syst Pharmacol. 2022 Apr;11:403-408. (SCI)

5. Chang CP, Chang YG, Chuang PY, Thi Ngoc Anh Nguyen, Wu KC, Chou FY, Cheng SJ, Chen HM, Jin LW, Carvalho K, Huin V, Buee L, Liao YF, Lin CJ, Blum D, Chern Y. Equilibrative nucleoside transporter 1 inhibition rescues energy dysfunction and pathology in a model of tauopathy. Acta Neuropathol Commun 2021; 9:112. (SCI)

6. Wu KC, Lee CY, Chern Y, Lin CJ*. Amelioration of lipopolysaccharide-induced memory impairment in equilibrative nucleoside transporter-2 knockout mice is accompanied by the changes in glutamatergic pathways. Brain Behavior and Immunity 2021; 96: 187–199. (*The corresponding author) (SCI)

7. Lai PH, Wang TH, Chang NY, Wu KC, Yao JCC, Lin CJ*. Changes of blood-brain-barrier function and transfer of amyloid beta in rats with collagen-induced arthritis. Journal of Neuroinflammation 2021; 18:35. https://doi.org/10.1186/s12974-021-02086-2.(* The corresponding author) (SCI)

8. Ho SY, Chen IC, Chang KC, Lin HR, Tsai CW, Lin CJ*, Liou HH*. Equilibrative nucleoside transporters-1 inhibitors act as anti-epileptic agents by inhibiting glutamatergic transmission. Frontiers in Neuroscience 2020; 14:610898. doi: 10.3389/fnins.2020.610898. (* The corresponding author) (SCI)

9. Wu KC, Lee CY, Chou FY, Chern Y, Lin CJ*. Deletion of equilibrative nucleoside transporter-2 protects against lipopolysaccharide-induced neuroinflammation and blood-brain barrier dysfunction in mice. Brain Behavior and Immunity 2020; 84:59-71. (* The corresponding author) (SCI)

10. Chiu WY, Lin CJ, Yang WS, Tsai KS, Reginster JY. Racial difference in bioavailability of oral ibandronate between Caucasian and Taiwanese postmenopausal women. Osteoporosis International 2019; doi: 10.1007/s00198-019-05127-y.(SCI)

11. Wu KC, Liou HH, Lee CY, Lin CJ*. Down-regulation of Nramp1 is associated with MPTP/MPP+-induced α-synuclein accumulation and neurotoxicity. Neuropathology and Applied Neurobiology. 2019; 45:157-173. (* The corresponding author) (SCI)

12. Wu KC, Lin CJ*. The regulation of drug-metabolizing enzymes and membrane transporters by inflammation: Evidences in inflammatory diseases and age-related disorders. Journal of Food and Drug Analysis 2019; 27:48-59. (* The corresponding author)(SCI)

13. Lee CC, Chang CP, Lin CJ, Lai HL, Kao YH, Cheng SJ, Chen HM, Liao YP, Faivre E, Buée L, Blum D, Fang J-M, Chern Y. Adenosine augmentation evoked by an ENT1 inhibitor improves memory impairment and neuronal plasticity in the APP/PS1 mouse model of Alzheimer’s disease. Molecular Neurobiology, 2018; doi: 10.1007/s12035-018-1030-z. (SCI)

14. Lin CH, Hsu KW, Chen CH, Uang YS, Lin CJ*. Differential changes in the pharmacokinetics of statins in collagen-induced arthritis rats. Biochemical Pharmacology 2017; 142: 216–228. (* The corresponding author)(SCI)

15. Wu KC, Liou HH, Kao YH, Lee CY, Lin CJ*. The critical role of Nramp1 in degrading α-synuclein oligomers in microglia under iron overload condition. Neurobiology of Disease 2017; 104:61-72. (* The corresponding author) (SCI)

16. Kao YH, Lin MS, Chen CM, Wu YR, Chen HM, Lai HL, Chern Y*, Lin CJ*. Targeting ENT1 and adenosine tone for the treatment of Huntington's disease. Human Molecular Genetics 2017; 26:467-478. (* The corresponding author) (SCI)

17. Kao YH, Chern Y, Yang HT, Chen HM, Lin CJ*. Regulation of P-glycoprotein expression in brain capillaries of Huntington’s disease transgenic mice and its impact on brain availability of antipsychotic agents risperidone and paliperidone. Journal of Cerebral Blood Flow and Metabolism 2016; 36:1412-1423. (* The corresponding author) (SCI)

18. Wu KC, Lu YH, Peng YH, Hsu LC, Lin CJ*. Effects of lipopolysaccaride on the expression of plasma membrane monoamine transporter at the blood-brain barrier and its implications to the transport of neurotoxins. Journal of Neurochemistry 2015; 135:1178-1188 (* The corresponding author) (SCI)

19. Wu KC, Lu YH, Peng YH, Tsai TF, Kao YH, Yang HT, Lin CJ*. Decreased expression of organic cation transporters, Oct1 and Oct2, in brain capillaries and its implication to MPTP-induced dopaminergic toxicity in aged mice. Journal of Cerebral Blood Flow and Metabolism. 2015; 35:37–47 (SCI) (* The corresponding author)

20. Yang JC, Lin CJ, Wang HL, Chen JD, Kao JY, Shun CT, Lu CW, Lin BR, Shieh MJ, Chang MC, Chang YT, Wei SC, Lin LC, Yeh WC, Kuo JS, Tung CC, Leong YL, Wang TH, Wong JM. Superiority of High-Dose Dual Therapy over Standard First-Line or Rescue Therapy for Helicobacter pylori Infection. Clinical Gastroenterology and Hepatology 2015; 13:895-905 (SCI)

21. Wang ST, Fang TF, Hsu C, Chen CH, Lin CJ, Su NW. Biotransformed product, genistein 7-O-phosphate, enhances the oral bioavailability of genistein. Journal of Functional Foods 2015; 13:323-335.(SCI)

22. Yang JC, Lu CW, Lin CJ*. The treatment of Helicobacter pylori infection - The current and the future. World Journal of Gastroenterology. 2014; 20:5283-5293 (SCI). (* The corresponding author)

23. Chen CL, Lin TC, Wang SY, Shie JJ, Tsai KC, Cheng YS, Jan JT, Lin CJ, Fang JM, Wong CH. Tamiphosphor monoesters as effective anti-influenza agents. European Journal of Medicinal Chemistry 2014; 81:106-118. (SCI)

24. Chen CH, Yang JC, Uang YS, Lin CJ*. Improved dissolution rate and oral bioavailability of lovastatin in red yeast rice products. International Journal of Pharmaceutics 2013; 444:18-24. (SCI) (* The corresponding author)

25. Lin TS, Liw YW, Song JS, Hsieh TC, Yeh HW, Hsu LC, Lin CJ, Wu SH, Liang PH. Synthesis and biological evaluation of novel C-aryl-D-glucofuranosides as sodium-dependent glucoses co-transporter 2 inhibitors. Bioorganic & Medicinal Chemistry 2013; 21:6282-6291. (SCI)

26. Chen CH, Yang JC, Uang YS, Lin CJ*. Differential inhibitory effects of proton pump inhibitors on the metabolism and antiplatelet activities of clopidogrel and prasugrel. Biopharm Drug Dispos. 2012; 33:278-283. (* The corresponding author) (SCI)

27. Yeh SY, Pan HJ, Lin CC, Kao YH, Chen YH, Lin CJ*. Hyperglycemia induced down-regulation of renal P-glycoprotein expression. Eur J Pharmacol. 2012; 690:42-50.(SCI) (* The corresponding author)

28. Chen CH, Uang YS, Wang ST, Yang JC, Lin CJ*. Interaction between red yeast rice and CYP450 enzymes/P-glycoprotein and its implication for the clinical pharmacokinetics of lovastatin. Evidence-Based Complementary and Alternative Medicine 2012; :Article ID127043.(SCI) (* The corresponding author)

29. Chang TT, Shyu MK, Huang MC, Hsu CC, Yeh SY, Chen MR, Lin CJ*. Hypoxia-mediated downregulation of OCTN2 and PPAR-alpha expression in human placentas and in BeWo cells. Molecular Pharmaceutics 2011; 8:117-125.(SCI) (* The corresponding author)

30. Yang JC, Wang HL, Chern HD, Shun CT, Lin BR, Lin CJ*. Role of omeprazole dosage and cytochrome P450 2C19 genotype in patients receiving omeprazole-amoxicillin dual therapy for Helicobacter pylori eradication.. Pharmacotherapy 2011; 31:227-238.(SCI) (* The corresponding author)

31. Huang NK, Lin JH, Lin JT, Lin CI, Liu EM, Lin CJ, Chen WP, Shen YC, Chen HM, Chen JB, Lai HL, Yang CW, Chiang MC, Wu YS, Chang C, Chen JF, Fang JM, Lin YL, Chern Y. A new drug design targeting the adenosinergic system for Huntington’s disease. PLoS ONE 2011; 6:e20934. (SCI)

32. Shyu MK, Chen CW, Lin NY, Liao WC, Chen CH, Lin CJ, Huang HC, Lee JJ, Huang MJ, Gseng GF, Shih JC, Lee CN, Hsieh FJ, Huang MC. MUC1 expression is elevated in severe preeclamptic placentas and suppresses trophoblast cell invasion via β1-integrin signaling. J Clin Endocrinol Metab. 2011; 96:3759-3767. (SCI)

33. Yang JC, Lin CJ*. CYP2C19 genotypes in the pharmacokinetics/pharmacodynamics of proton pump inhibitor-based therapy of Helicobacter pylori infection. Expert Opinion on Drug Metabolism & Toxicology 2010; 6:29-41.(SCI) (* The corresponding author)

34. Lin CJ*, Tai Y, Huang MT, Tsai YF, Hsu HJ, Tzen KY, Liou HH. Cellular localization of the organic cation transporters, OCT1 and OCT2, in brain microvessel endothelial cells and its implication for MPTP transport across the blood-brain barrier and MPTP-induced dopaminergic toxicity in rodents.. Journal of Neurochemistry 2010; 114:717-727(SCI) (* The corresponding author)

35. Huang FD, Kung FL, Tseng YC, Chen MR, Lin CJ*. Regulation of protein expression and function of OCTN2 in forskolin-induced syncytialization in BeWo cell. Placenta. 2009;30:187-194.(SCI) (* The corresponding author)

36. Wu KC, Pan HJ, Yin HS, Chen MR, Lu SC, Lin CJ*. Change in P-glycoprotein and caveolin protein expression in capillaries of the brain striatum in New Zealand Obese mice with type 2 diabetes. Life Sciences 2009; 85:775-781(SCI) (* The corresponding author)

37. Yang JC, Yang YF, Uang YS, Lin CJ*, Wang TH. Pharmacokinetic/pharmacodynamic analysis of the role of CYP2C19 genotypes in short-term rabeprazole-based triple therapy against Helicobacter pylori. British Journal of Clinical Pharmacology. 2009; 67:503-510(SCI) (* The corresponding author)

38. Lin CJ, Yen MF, Hu OYP, Lin MS, Hsiong CH, Liou HH. Association of galactose single-point test levels and phenytoin metabolic polymorphisms with gingival hyperplasia in patients receiving long-term phenytoin therapy. Pharmacotherapy. 2008; 28:35-41(SCI)

39. Yeh WL, Lin CJ, Fu WM. Enhancement of glucose transporter expression of brain endothelial cells by vascular endothelial growth factor derived from glioma exposed hypoxia. Molecular Pharmacology. 2008; 73:170-177(SCI)

40. Hung CC, Chen CC, Lin CJ, Liou HH. Functional evaluation of polymorphisms in the human ABCB1 gene and the impact on clinical responses of antiepileptic drugs. Pharmacogenetics and Gemonics. 2008; 18:390-402(SCI)

41. Chen CH, Hsu HJ, Huang YJ, Lin CJ*. Interaction of flavonoids and intestinal facilitated glucose transporters. Planta Medica 2007; 348-354:348-354. (SCI) (* The corresponding author)

42. Yeh WL, Lu DY, Lin CJ, Liou HC, Fu WM. Inhibition of Hypoxia-Induced Increase of Blood-Brain Barrier Permeability by YC-1 through the Antagonism of HIF-1?Accumulation and VEGF Expression. Molecular Pharmacology 2007; 72:440-449(SCI)

43. Liou HH, Hsu HJ, Tsai YF, Shih CY, Chang YC, Lin CJ*. Interaction between nicotine and MPTP/MPP+ in rat brain endothelial cells. Life Sciences 2007; 81:664-672(SCI) (* The corresponding author)

44. Yeh TC, Chiang PC, Li TK, Hsu JL, Lin CJ, Wang SW, Peng CY, Guh JH. Genistein induces apoptosis in human hepatocellular carcinomas via interaction of endoplasmic reticulum stress and mitochondrial insult. Biochemical Pharmacology 2007; 73:782-792.(SCI)

45. Lin CJ, Chen CH, Liu FW, Kang JJ, Chen CK, Lee SL, Lee SS. Inhibition of intestinal glucose uptake by aporphines and secoaporphines.. Life Sciences 2006; 79:144-153. (SCI)

46. Lin CJ, Wu MH, Hsueh YM, Sun SSM, Cheng AL. Tissue Distribution of Arsenic Species in Rabbits after Single and Multiple Parenteral Administration of Arsenic Trioxide:Tissue accumulation and the reversibility after washout are tissue-selective. Cancer Chemother Pharmacol. 2005; 55:170-178.(SCI)

47. Hung CC, Tai JJ, Lin CJ, Lee MJ, Liou HH. Impact of complex polymorphic system of ABCB1 gene on the epilepsy treatment outcome.. Pharmacogenomics 2005; 6:411-417. (SCI)

48. Hung CC, Lin CJ, Chen CC, Chang CJ, Liou HH. Dosage recommendation of phenytoin for patients with epilepsy with different CYP2C9/CYP2C19 polymorphisms. Ther Drug Monit 2004; 26:534-540. (SCI)

49. Wu SP, Shyu MK, Liou HH, Gau CS, Lin CJ*. Interaction between anticonvulsants and human placental carnitine transporter.. Epilepsia 2004; 45:204-210. (SCI) (* The corresponding author)

50. Lin CJ, Yang JC, Uang YS, Chern HD, Wang TH. Time-dependent amplified pharmacokinetic/pharmacodynamic response of rabeprazole in CYP2C19 poor metabolizers. Pharmacotherapy 2003; 23:711-719. (SCI)

51. Wu MH, Lin CJ, Chen CL, Su MJ, Sun S, Cheng AL. Direct cardiac effects of acute and chronic parenteral administration of As2O3 in rabbits: Evidence of reversible chronic toxicity and tissue accumulation of arsenites.. Toxicol Appl Pharmacol 2003; 189:214-220. (SCI)

52. Lin CJ, Akarawut W, Smith DE. Competitive inhibition of Glycylsarcosine transport by enalapril in rabbit renal brush border membrane vesicles: Interaction of ACE inhibitors with high-affinity H+/peptide symporter. Pharmaceutical Research 1999; 16: 609-615. (SCI)

53. Lin CJ, Smith DE. GlySar uptake in rabbit renal BBMV isolated from outer-cortex or outer-medulla: Evidence for heterogeneous distribution of oligopeptide transporters. AAPS PharmSci 1999; 1: 1-6. (SCI)

54. Akarawut W, Lin CJ, Smith DE. Noncompetitive inhibition of glycylsarcosine transport by quinapril in rabbit renal brush border membrane vesicles: Effect on high-affinity peptide transporter. Journal of Pharmacology and Experimental Therapeutics 1998; 287: 684-690. (SCI)